Moderna Stock News

Highlights Greg Hunt announces Novavax roll out date, will be available from Monday (14 February 2022). A three million dose shipment of the protein-based Covid vaccine has arrived in Australia already. Novavax Inc.s (NYSE:NVAX) protein vaccine will be available to Aussies from Valentines day (14 February 2022). The first shipment of vaccines has already arrived to help boost Australian immunity against Covid and its persisting variant Omicron. The two-dose vaccine is under media spotlight since it got itss approval from the Australian Technical Advisory Group on Immunisation (ATAGI ) and Therapeutic Goods Association (TGA). As announced by Federal Health Minister Greg Hunt, the Novavax covid vaccine will be rolled out across Australia from Monday. Where can you get the Novavax vaccine? The vaccine shots will be administered at state clinics and select general practitioners and pharmacies in the country. As per reports, the vaccine will be supplied to other pharmacies and practitioners from February 21.

The research, released on Thursday, found that Moderna''s vaccine was 93.2% effective in reducing symptomatic COVID cases. More updates.

Moderna, Inc.

AstraZeneca raised its annual dividend for the first time in a decade on Thursday, February 10, and forecast higher sales for 2022 as new drugs against cancer, kidney disease, and rare conditions make up for a decline in COVID-19 products. Early data has shown a booster shot of the drugmakers widely-used COVID-19 vaccine and its antibody drug Evusheld both work against the Omicron coronavirus variant. But while the company forecasts sales of Evusheld to grow this year, it expects that will be more than outweighed by a decline in sales of the vaccine amid growing competition. AstraZeneca has started earning a modest profit on the vaccine, which was initially sold at-cost under a deal with its developers at Oxford University. But the company said it would continue to sell it to low-income nations on a non-profit basis. While sales of COVID-19 products are expected to decline by a low-to-mid 20s percentage this year, the London-listed company forecast overall revenues to rise by a high teens percentage, with core earnings up by a mid-to-high 20s percentage.

Canberra, Feb 10 (IANS) Australia has provisionally approved the use of the AstraZeneca vaccine against Covid-19 as a booster shot for people aged 18 years and older. However, in its announcement the Therapeutic Goods Administration (TGA) said that Pfizer and Modernas mRNA vaccines remain the preferred boosters for Australians irrespective of the primary vaccine a [] The post AstraZeneca approved as booster vaccine in Australia appeared first on Buziness Bytes .

AstraZeneca recorded a big jump in revenue on Thursday as it begins to take a profit from its coronavirus vaccine for the first time. The company recorded full-year revenues of $37.4 billion, an increase of 38% from the year before at constant exchange rates. Part of the boost came from $4 billion in sales of its COVID-19 vaccine, developed with the University of Oxford. Despite rising revenue, AstraZeneca reported a pre-tax loss of $265 million due to costs from its purchase of U.S. drug company Alexion Pharmaceuticals and new drug research. The Anglo-Swedish drugmaker said in November it would begin to take a "modest" profit from the COVID-19 shot, which it had been providing "at cost" - around $2 to $3 -following an agreement with Oxford. Other COVID-19 vaccine producers, such as Pfizer and Moderna, have been booking hefty profits on their shots all along. In the three months to September, the company said revenue jumped by about 50%, to a record $9.9 billion. The increase was due to sales of more than $1 billion in COVID-19 vaccines and the inclusion for the first time of some $1.3 billion worth of revenue from its rare disease business unit following the recent acquisition of Alexion.

It depends on how much you care about the "bargain" part.

They''ve both been crashing in recent months, but which stock is more likely to recover?

Shares of vaccine makers rebound Wednesday after Pfizer''s 2022 sales guidance fell short of Wall Street''s bullish expectations.

A sell-off in growth stocks and a setback for a vaccine mandate pushed the stock lower.

Investors sold shares of Pfizer, Moderna and Novavax after the US pharma giant made sales forecasts for its coronavirus and pill that fell short of market expectations.

The U.S pharmaceutical Moderna has signed a supply agreement with Colombia for 10.8 million doses of its COVID-19 vaccine.

Johnson & Johnson has quietly paused production of its Covid vaccine, according to a media report US multinational Johnson & Johnson suspended production of its Covid-19 vaccine late last year amid a massive push by the federal government and health officials to promote getting inoculated, The New York Times reported on Tuesday, citing sources familiar with the situation. The pause in production is reportedly temporary, but the one plant producing the vaccine in the Dutch city of Leiden has apparently shifted its focus to producing a potentially more profitable vaccine for an unrelated virus. Its unclear if the production pause has affected the availability of the single-jab Covid vaccine, as the company has a stockpile of doses. However, one person familiar with the situation says the suspension could mean a reduction in output of a few hundred million doses. The plant is expected to produce more after a few months break. Other facilities are awaiting regulatory approval or to actually be up and running to produce the Johnson & Johnson vaccine, according to the NYT report.

Moderna will supply Colombia with an additional 10.8M doses of its COVID-19 vaccine.

Pfizer projected Tuesday that it will generate a record-shattering $32 billion in revenue from its publicly funded coronavirus vaccine in 2022 as the U.S. pharmaceutical giant refuses to share its technology with other nations, leaving billions of people around the world without access to lifesaving shots as the pandemic continues to rage. "Big Pharma has made more than enough money from this crisis," said the U.K.-based advocacy group Global Justice Now. "It''s time to suspend patents and break vaccine monopolies." While a portion of Pfizer''s mRNA-based vaccine recipe was leaked last year, the pharmaceutical firm and its German partner BioNTech have closely guarded the details of their manufacturing process, allowing the companies to rake in huge profits by selling their Covid-19 shots at a price tag well above the cost of production. On Tuesday, Pfizer reported that its profits increased roughly fourfold to $3.4 billion in the fourth quarter of 2021, beating analysts'' expectations. "It''s nothing short of pandemic profiteering for Pfizer to make a killing while its vaccines have been withheld from so many," Tim Bierley, a pharma campaigner at Global Justice Now, said in a statement. "Pfizer is now richer than most countries; it has made more than enough money from this crisis." In an analysis published in July, The People''s Vaccine Alliance noted that "Pfizer/BioNTech are charging their lowest reported price of $6.75 [per dose] to the African Union, but this is still nearly six times more than the estimated potential production cost of this vaccine." "One dose of the vaccine costs the same as Uganda spends per citizen on health in a whole year," the coalition observed.